What is Fiocruz, and what we do?
Highlights on Projects

All Fiocruz actions are oriented towards societal needs. We do this in various ways by deploying different technologies: hard technologies to prevent, to detect and to treat diseases; and soft technologies with social purposes.

Here are some examples of Fiocruz projects that has helped to improve not only Brazilian citizen’s life, but also helped the world to fight several diseases, and increase health standards worldwide.

The technologies with social purposes are set of techniques, transformative methodologies, developed and/or applied in the interaction with the population and appropriate for it, which represent solutions for social inclusion and improvement of living conditions.

Click at the images for description of the projects

OTSS - Bocaina

is a partnership between the forum of traditional communities of Angra dos Reis (RJ), Paraty (RJ) and Ubatuba (SP).

The aim is promoting well-being, expanding and qualifying sustainable development in the traditional territories of the Bocaina region along with caiçara, indigenous and quilombola traditional populations.

HMB - Fiocruz

Fiocruz has been madding investments since 1985 in research and technological development in the area of Human Milk Banks (HMBs), which allowed Brazil to develop a model of HMBs.

The Human Milk Banks (HMB) have historically played an important role in child healthcare in Brazil. In the field of public health, HMB are considered as a strategy of state policy focused on food and nutritional security, aiming at reducing infant morbidity and mortality with emphasis on the neonatal component.


Ações para o enfrentamento da mortalidade materna e infantil

Here we are presenting some examples of diseases we are fighting among various tropical, rare, neglected and chronic diseases

Click at the images for description of the projects


Vigilância em arboviroses


Among these diseases, HIV/AIDS is an enormous challenge worldwide. Fiocruz is fighting HIV/AIDS through: manufacturing and supplying serological multi-tests to detect HIV, Syphilis, Hepatitis B and C; Toxoplasmosis and Chagas Disease with a carry-on equipment ready to georeferencing and IoT; Point of Care Tests to detect HIV and Syphilis; Molecular (PCR) tests to detect HIV, Hepatitis B and C and Malaria for blood transfusion safety; Efavirenz to treat HIV; HIV pre-exposure prophylaxis study to support the health system; and health care to people living with HIV/AIDS.


Fiocruz is also fighting Hansen’s Disease, a neglected disease with high disease burden in Brazil. In partnership with Novartis, we  developed a molecular in vitro diagnostics to detect M. leprae DNA based on precision medicine in order to address this disease in an affordable way. Fiocruz is also developing a high resolution digital photography technology to detect leprosy.


Malaria is a tropical disease with high morbidity rates. Fiocruz is fighting malaria trough: the manufacturing of a molecular test manufacturing to detect HIV, Hepatitis B and C and Malaria used in blood banks in the Brazilian Health System; the development of a fixed dose combination of Artesunate plus Mefloquine and a pediatric Artesunate plus Mefloquine. This latter development is a result of a partnership with the Drugs for Neglected Disease Initiative (DNDi).


Among chronic diseases, cancer is a huge challenge to all societies independent of race, geography or social condition. Fiocruz is fighting cancer trough R&D to detect specific cancer targets such as HER2 in the Breast Cancer. Fiocruz has also signed a partnership with Samsung Bioeps for the technology transfer of Trastuzumab, a monoclonal antibody to treat Breast Cancer HER2+. Other strategic alliances are ongoing for the technology transfer of other monoclonal antibodies to treat several types of cancer, such as Rituximab and Bevacizumab. Fiocruz also manufacturers Imatinib Mesylate to treat acute lymphoblastic leukemia. Finally yet importantly, Fiocruz has also established a network called Fio-cancer to pull together her collaborators think about cancer.


Autoimmune diseases is a big challenge to all societies independent of race, geography or social condition. Fiocruz is fighting them trough: partnerships for the technology transfer of biopharmaceuticals with different companies regarding products such as Adalimumab, Etanercept, Tocilizumab, Certolizumab and Rituximab. Besides manufacturing and supply to the Brazilian Ministry of Fiocruz, one of the biggest challenges is to to reduce the governmental costs related to these high-costs products purchased by Brazilian Ministry of Heatlh.


Among these diseases, Zika, Dengue and Chikungunya are big challenges worldwide. Fiocruz is fighting these diseases through R&D and manufacturing of diagnostics and vaccines. In diagnostics, Fiocruz manufacturers a molecular test for Zika, Dengue and Chikungunya; point of care tests to detect Zika IgM/IgG, Chikungunya IgM/IgG, Dengue IgM/IgG and Zika. All these diagnostics are used in the Brazilian Surveillance Network. Fiocruz is also developing a qPCR LAb-on-a-Chip technology to detect Zika, Dengue (all 4 serotypes), Chikungunya and Yellow Fever. In vaccines, Fiocruz is one of the main international manufacturers of the yellow fever vaccine. More recently started the development of a Zika Vaccine in two different approaches – live-attenuated and inactivated vaccine.
Manufacturing biopharmaceuticals and Vaccines and IVDs

Among the large range of activities done by the several institutes at Fiocruz, the development and manufacturing of pharmaceuticals, vaccines, diagnostics and biological medicines has a very important role in the Brazilian Health System. By providing affordable and sustainable products due to local manufacturing, Fiocruz supports the Brazilian Government pharmaceutical assistance programs, having a daily impact on people`s health.

Such challenges are part of the work done by two Fiocruz institutes: Bio-Manguinhos and Farmanguinhos. Both institutes work in collaboration within Fiocruz innovation ecossystem, as well as with other organizations around the world.

Bio-Manguinhos, the Fiocruz institute responsible for development and manufacturing of vaccines, diagnostics and biopharmaceuticals

Bio-Manguinhos is the biggest and most modern governmental owned institute for R&D and manufacturing of vaccines, in vitro diagnostics (IVDs) and biopharmaceuticals in Brazil. As part of Fiocruz system, Bio-Manguinhos plays a strategic role in supply of several pediatric vaccines for around 3 million newborns per year in Brazil, and is a WHO pre-qualified manufacturer to supply vaccines for more than 70 countries worldwide, according to United Nations Agencies request, mostly PAHO and UNICEF. Regarding diagnostics, Bio-Manguinhos delivers 17 IVDs for several diseases and has an important role for the surveillance system and for safe blood transfusion. In biopharmaceuticals, Bio-Manguinhos has invested in products that has both major impact for the sustainability of MoH medicines acquisition and for the population’s health.

FarManguinhos, the Fiocruz institute responsible for medicines manufacturing

Farmanguinhos contributes with nearly 40% of the drug purchased by the Ministry of Health from public labs, representing 5% of Ministry of Health expenditures with medicines purchase. This means that Fiocruz is responsible to maintain sustainable and affordable medicines supply.

Farmanguinhos generates savings to the government budget, especially due to the manufacturing of medicines used in HIV/AIDS treatment, allowing the government to regulate prices charged by other laboratories and even to determine compulsory licensing of medicines, as occurred with Efavirenz, an antiretroviral.

A bridge between discovery and Market

In order to be successful in R&D in biologicals, having scaling-up capabilities and infrastructure is key. Such capabilities allow closing the gap between drug discovery and market introduction. Fiocruz Pilot Plant will provide CDMO services for clinical trials batches and other scaling-up services attending not only Fiocruz biological products development ecosystem, but also other institutions, public and private, in the Brazilian Health Industry Complex.